Ultragenyx Pharmaceutical (RARE) Current Assets (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Current Assets of $657.0 million for Q1 2026, down 6.03% year-over-year from $699.2 million in Q1 2025, and down 30.91% on a QoQ basis from $951.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Current Assets data on file, last reported at $657.0 million in Q1 2026.
- Quarterly Current Assets fell 6.03% year-over-year to $657.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $657.0 million (down 6.03% YoY) and the FY2025 annual result came in at $951.0 million, up 16.4% from the prior year.
- Current Assets fell to $657.0 million in Q1 2026 per RARE's latest filing, from $951.0 million in the prior quarter.
- Across five years, Current Assets topped out at $1.0 billion in Q3 2022 and bottomed at $596.0 million in Q1 2024.
- The 5-year median for Current Assets is $719.8 million (2025), against an average of $760.6 million.
- The widest annual swing landed in 2023, when Current Assets slumped 40.83%; it then surged 37.39% in 2024.
- Tracing RARE's Current Assets over 5 years: stood at $883.9 million in 2022, then fell by 17.16% to $732.2 million in 2023, then rose by 11.58% to $817.0 million in 2024, then advanced by 16.4% to $951.0 million in 2025, then plunged by 30.91% to $657.0 million in 2026.
- Per Business Quant, the three latest RARE Current Assets figures stand at $657.0 million (Q1 2026), $951.0 million (Q4 2025), and $643.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | 657.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 657.00 Mn |
| Dec 31, 2025 | 951.00 Mn |
| Sep 30, 2025 | 643.21 Mn |
| Jun 30, 2025 | 719.79 Mn |
| Mar 31, 2025 | 699.16 Mn |
| Dec 31, 2024 | 817.00 Mn |
| Sep 30, 2024 | 799.61 Mn |
| Jun 30, 2024 | 964.64 Mn |
| Mar 31, 2024 | 595.97 Mn |
| Dec 31, 2023 | 732.18 Mn |
| Sep 30, 2023 | 599.19 Mn |
| Jun 30, 2023 | 702.14 Mn |
| Mar 31, 2023 | 766.34 Mn |
| Dec 31, 2022 | 883.90 Mn |
| Sep 30, 2022 | 1.01 Bn |
| Jun 30, 2022 | 678.54 Mn |
| Mar 31, 2022 | 707.52 Mn |
| Dec 31, 2021 | 856.60 Mn |
| Sep 30, 2021 | 846.88 Mn |
| Jun 30, 2021 | 949.49 Mn |
| Mar 31, 2021 | 1.07 Bn |
| Dec 31, 2020 | 1.30 Bn |
| Sep 30, 2020 | 872.00 Mn |
| Mar 31, 2020 | 894.32 Mn |
| Dec 31, 2019 | 851.02 Mn |
| Sep 30, 2019 | 613.49 Mn |
| Jun 30, 2019 | 699.43 Mn |
| Mar 31, 2019 | 786.89 Mn |
| Dec 31, 2018 | 522.37 Mn |
| Sep 30, 2018 | 567.48 Mn |
| Jun 30, 2018 | 604.74 Mn |
| Mar 31, 2018 | 581.58 Mn |
| Dec 31, 2017 | 269.58 Mn |
| Sep 30, 2017 | 390.90 Mn |
| Jun 30, 2017 | 419.79 Mn |
| Mar 31, 2017 | 444.69 Mn |
| Dec 31, 2016 | 401.70 Mn |
| Sep 30, 2016 | 416.79 Mn |
| Jun 30, 2016 | 411.08 Mn |
| Mar 31, 2016 | 430.23 Mn |
| Dec 31, 2015 | 450.21 Mn |
| Sep 30, 2015 | 460.71 Mn |
| Jun 30, 2015 | 336.53 Mn |
| Mar 31, 2015 | 350.51 Mn |
| Dec 31, 2014 | 193.42 Mn |
| Sep 30, 2014 | 206.74 Mn |
| Jun 30, 2014 | 158.22 Mn |
| Mar 31, 2014 | 169.64 Mn |
| Dec 31, 2013 | 55.23 Mn |